Last reviewed · How we verify
M5049 medium dose
At a glance
| Generic name | M5049 medium dose |
|---|---|
| Also known as | Enpatoran |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) (PHASE2)
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) (PHASE2)
- Study of M5049 in Healthy Japanese and Caucasian Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: